Ajo LP trimmed its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 41.5% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 2,407,395 shares of the biopharmaceutical company’s stock after selling 1,706,756 shares during the period. Ajo LP owned 0.18% of Gilead Sciences worth $170,395,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other hedge funds and other institutional investors have also recently made changes to their positions in the business. Keel Point LLC boosted its holdings in shares of Gilead Sciences by 0.4% in the first quarter. Keel Point LLC now owns 3,111 shares of the biopharmaceutical company’s stock worth $211,000 after acquiring an additional 11 shares during the period. West Oak Capital LLC boosted its holdings in shares of Gilead Sciences by 0.7% in the second quarter. West Oak Capital LLC now owns 4,666 shares of the biopharmaceutical company’s stock worth $330,000 after acquiring an additional 32 shares during the period. First Heartland Consultants Inc. boosted its holdings in shares of Gilead Sciences by 0.4% in the second quarter. First Heartland Consultants Inc. now owns 8,927 shares of the biopharmaceutical company’s stock worth $632,000 after acquiring an additional 39 shares during the period. Arrow Financial Corp boosted its holdings in shares of Gilead Sciences by 0.3% in the second quarter. Arrow Financial Corp now owns 17,771 shares of the biopharmaceutical company’s stock worth $1,258,000 after acquiring an additional 45 shares during the period. Finally, Westover Capital Advisors LLC boosted its holdings in shares of Gilead Sciences by 0.8% in the first quarter. Westover Capital Advisors LLC now owns 5,563 shares of the biopharmaceutical company’s stock worth $378,000 after acquiring an additional 46 shares during the period. 74.62% of the stock is owned by institutional investors and hedge funds.
In related news, EVP Gregg H. Alton sold 50,000 shares of the firm’s stock in a transaction dated Wednesday, August 30th. The stock was sold at an average price of $79.00, for a total value of $3,950,000.00. Following the sale, the executive vice president now directly owns 113,237 shares of the company’s stock, valued at $8,945,723. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider John F. Milligan sold 220,000 shares of the firm’s stock in a transaction dated Monday, November 13th. The stock was sold at an average price of $72.88, for a total value of $16,033,600.00. The disclosure for this sale can be found here. Insiders sold 666,819 shares of company stock worth $52,303,086 over the last three months. 1.30% of the stock is owned by insiders.
COPYRIGHT VIOLATION WARNING: This report was first reported by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are reading this report on another publication, it was illegally copied and reposted in violation of United States and international copyright laws. The original version of this report can be viewed at https://ledgergazette.com/2017/11/19/ajo-lp-trims-holdings-in-gilead-sciences-inc-gild.html.
A number of equities analysts have recently commented on the company. Leerink Swann raised their price target on Gilead Sciences from $84.00 to $85.00 and gave the stock a “market perform” rating in a report on Thursday, October 19th. BMO Capital Markets reaffirmed an “outperform” rating and issued a $82.00 price target (up from $72.00) on shares of Gilead Sciences in a report on Thursday, July 27th. BidaskClub lowered Gilead Sciences from a “buy” rating to a “hold” rating in a report on Wednesday, August 9th. Cowen and Company reaffirmed an “outperform” rating and issued a $90.00 price target on shares of Gilead Sciences in a report on Thursday, July 27th. Finally, Berenberg Bank reaffirmed a “buy” rating and issued a $86.00 price target (up from $79.00) on shares of Gilead Sciences in a report on Sunday, August 20th. One research analyst has rated the stock with a sell rating, twelve have assigned a hold rating, eighteen have issued a buy rating and one has given a strong buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus target price of $84.87.
Gilead Sciences, Inc. (GILD) opened at $72.44 on Friday. The company has a market capitalization of $94,626.13, a PE ratio of 7.56, a PEG ratio of -1.21 and a beta of 1.13. The company has a quick ratio of 3.56, a current ratio of 3.68 and a debt-to-equity ratio of 1.10. Gilead Sciences, Inc. has a twelve month low of $63.76 and a twelve month high of $86.27.
Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported $2.27 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $2.13 by $0.14. The firm had revenue of $6.51 billion for the quarter, compared to the consensus estimate of $6.40 billion. Gilead Sciences had a return on equity of 57.15% and a net margin of 42.22%. The company’s quarterly revenue was down 13.2% on a year-over-year basis. During the same quarter in the previous year, the business earned $2.75 earnings per share. research analysts expect that Gilead Sciences, Inc. will post 8.53 EPS for the current year.
The business also recently disclosed a quarterly dividend, which will be paid on Thursday, December 28th. Stockholders of record on Friday, December 15th will be issued a $0.52 dividend. The ex-dividend date of this dividend is Thursday, December 14th. This represents a $2.08 annualized dividend and a dividend yield of 2.87%. Gilead Sciences’s dividend payout ratio is currently 23.69%.
Gilead Sciences Profile
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.